Identification of Epigenomic Drivers and Predictors of Chordoma Development and Recurrence

脊索瘤占原发性脊柱和颅底肿瘤的20%，尽管标准治疗手术和术后放疗，中位生存期仍为6-7年。脊索瘤复发的患者的预后较差

Chordomas represent 20% of primary spine and skull base tumours and median survival remains poor at 6-7 years despite standard treatment of surgery and post-operative radiotherapy. Patients that develop a recurrence of their chordoma experience poorer sur